Mariner
CRSP icon

Mariner’s CRISPR Therapeutics CRSP Stock Holding History

Mariner’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Sell
6,030
-7,461
-55% -$393K ﹤0.01% 2773
2026
Q1 		$642K Sell
13,491
-3,418
-20% -$180K ﹤0.01% 2298
2025
Q4 		$886K Buy
16,909
+2,877
+21% +$172K ﹤0.01% 2030
2025
Q3 		$909K Buy
14,032
+2,086
+17% +$120K ﹤0.01% 1987
2025
Q2 		$581K Buy
+11,946
New +$462K ﹤0.01% 2210
2025
Q1 		– Sell
-5,765
Closed -$227K – 3470
2024
Q4 		$227K Sell
5,765
-746
-11% -$35.2K ﹤0.01% 2893
2024
Q3 		$306K Sell
6,511
-274
-4% -$13.9K ﹤0.01% 2553
2024
Q2 		$367K Sell
6,785
-1,413
-17% -$81.7K ﹤0.01% 2297
2024
Q1 		$559K Buy
8,198
+2,162
+36% +$155K ﹤0.01% 1943
2023
Q4 		$378K Sell
6,036
-1,454
-19% -$80.4K ﹤0.01% 2151
2023
Q3 		$340K Buy
7,490
+938
+14% +$48.4K ﹤0.01% 2048
2023
Q2 		$368K Buy
+6,552
New +$372K ﹤0.01% 1965
2022
Q4 		– Sell
-3,586
Closed -$234K – 2759
2022
Q3 		$234K Buy
+3,586
New +$260K ﹤0.01% 1948

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mariner's CRSP Position: Q2 2026 in Review

Mariner reduced its CRISPR Therapeutics (CRSP) stake by 55% in Q2 2026, selling an estimated $393K and leaving 6,030 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

Mariner first reported a position in CRSP in Q3 2022 and has held it in 13 quarters since. The position peaked at $909K in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mariner held 6,030 shares of CRISPR Therapeutics worth $329K as of Q2 2026.
  • Mariner sold 7,461 CRISPR Therapeutics shares in Q2 2026, an estimated $393K.
  • CRISPR Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2773 holding.
  • Mariner first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • Mariner's CRISPR Therapeutics position peaked at $909K in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.